A recent editorial examined research findings on how low levels of high-density lipoprotein (HDL) in the blood affect bone health, resulting in cartilage dysfunction and the development of osteoarthritis (OA). Authors note that a high-fat diet in mice with HDL deficiency resulted in OA development; thus, they conclude that in patients with metabolic syndrome, HDL may have a causative relationship to OA…
Two studies have shown that romosozumab is effective for increasing bone mineral density in both men and women with osteoporosis. And due to safety concerns, Janssen has dropped out of clinical trials for fulranumab, which is being studied to treat OA pain…
NEW YORK (Reuters Health)—The investigational drug abaloparatide may help postmenopausal women increase their bone mineral density (BMD) and reduce their risk of fracture, new industry research suggests. “What was surprising and very important about this study was that, although some drugs for osteoporosis don’t work across all patient subgroups, abaloparatide provided persistent protection against fracture…
SAN FRANCISCO—The discovery of a promising new target for the treatment of osteoporosis has a beginning to the story that, when it comes to scientific breakthroughs, rings familiar: It started with a disappointment. Researchers in the lab of Laurie H. Glimcher, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College—were in search…
Abaloparatide has completed clinical trials, which showed the treatment to be safe and effective in reducing fracture rates in postmenopausal women with osteoporosis. Also, XmAb5871 is being studied to treat systemic lupus erythematosus and doesn’t destroy B cells…
(Reuters Health)—Women who maintain an overall healthy diet may benefit from a slightly reduced risk of hip fractures later in life, according to a new U.S. study. Women who followed a Mediterranean-style diet were about three tenths of a percent less likely to break a hip over about 16 years, compared to women who didn’t…
NEW YORK (Reuters Health)—The combination of denosumab and teriparatide improves bone microarchitecture and estimated strength more than either drug alone in women with severe postmenopausal osteoporosis, researchers have found. Dr. Joy Tsai, from Massachusetts General Hospital in Boston, and colleagues conducted a single-site, two-year, open-label, randomized controlled trial involving 94 women aged 45 or older…
SAN FRANCISCO—Post-menopausal women with osteoporosis, previously treated with oral bisphosphonates, had greater increases in bone density when taking denosumab compared with zoledronic acid over a year’s time, according to a study presented at the 2015 ACR/ARHP Annual Meeting. The findings were discussed in the Discovery 2015 plenary session, which focused on new research. In the…
NEW YORK (Reuters Health)—Routine osteoporosis screening in men is a good value and effective based on a cost-effectiveness model, researchers say. “Osteoporosis is not just a disease for women. Osteoporosis affects many men (approximately 2 million in the U.S.), with significant morbidity, mortality, and costs that are projected to rise with the aging of the…
NEW YORK (Reuters Health)—The early elevation in intact parathyroid hormone (iPTH) seen with denosumab treatment is not associated with increased bone formation, according to research from Eli Lilly and Company. Denosumab is a member of the anticatabolic/antiresorptive class of drugs used to treat osteoporosis; iPTH levels are increased in the first several months after denosumab…